Is Your Organization Ready to Recapture Some of the $3 Billion Lost Each Year to Drug Wastage?
Have single-dose vials, dose, and waste, created a reimbursement challenge?
In RJ Health’s New White Paper “Addressing Drug Wastage: A $3 Billion Challenge” by: Todd Cooperman PharmD, MBA, R.Ph. Senior Vice President, Clinical Insights and Analytics & Manoj Kumar MBA, CPHIMS Senior Vice President, Products and Innovation
We examine:
-
What Drug Wastage is
-
How it occurs
-
The size and scope of the wastage challenge
-
Who it impacts
-
How it can be addressed
Drug wastage has significant cost ramifications to:
-
Providers – who may face audits or penalties for over-payments
-
Health Plans & Payors – where overall spend increases flow downstream and impact providers and patients
-
Patients – who absorb the increases in the overall cost of therapy and substantial premium increases
Readers will learn about:
-
Therapeutic classes with some multi-dose NDC options vs those with only single-does NDCs
-
Examples of average dosing, available vial size combinations and potential waste
-
Wastage percentages within select therapeutic classes
-
Average Wastage WAC per Claim of Top Specialty Drugs
-
How Drug Wastage can be Addressed and specific solutions